VBI Vaccines (VBV) Stock Price, News & Analysis

Company Overview

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1,300 shs
• Average Volume: 3,637 shs
• Market Capitalization: C$308.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VBV Stock Analysis - Frequently Asked Questions

How do I buy shares of VBI Vaccines?

Shares of VBV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VBI Vaccines investors own include Adobe (ADBE), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), Teladoc Health (TDOC), Tesla (TSLA), VBI Vaccines (VBIV) and Altimmune (ALT).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:VBV
• CUSIP: N/A
• CIK: N/A
• Web: www.vbivaccines.com
• Phone: +1-617-8303031
• Fax: N/A
• Employees: 22
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 14.29
• Current Ratio: 2.64
• Quick Ratio: 2.54

Sales & Book Value

• Annual Sales: C$3.36 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$1.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 64,079,000
• Free Float: N/A
• Market Cap: C$308.86 million
• Optionable: Not Optionable
• Beta: N/A